EA200970957A1 - Лекарственная комбинация и её применение при лечении атрофии мышечной ткани - Google Patents
Лекарственная комбинация и её применение при лечении атрофии мышечной тканиInfo
- Publication number
- EA200970957A1 EA200970957A1 EA200970957A EA200970957A EA200970957A1 EA 200970957 A1 EA200970957 A1 EA 200970957A1 EA 200970957 A EA200970957 A EA 200970957A EA 200970957 A EA200970957 A EA 200970957A EA 200970957 A1 EA200970957 A1 EA 200970957A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- atrophia
- application
- drug combination
- muscular tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
Abstract
Настоящим изобретением является продукт, содержащий β2-агонист и прогестин, в виде комбинации для раздельного, одновременного или последовательного применения в лечении или предотвращении атрофии мышечной ткани. Настоящим изобретением является также β2-агонист, выбранный из R,R-формотерола, индакатерола или ритодрина, предназначенный для применения в лечении или предотвращении атрофии мышечной ткани.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0707931A GB0707931D0 (en) | 2007-04-24 | 2007-04-24 | New Therapeutic use |
GB0707930A GB0707930D0 (en) | 2007-04-24 | 2007-04-24 | New therapeutic use |
GB0710101A GB0710101D0 (en) | 2007-05-25 | 2007-05-25 | New Therapeutic use |
PCT/GB2008/001452 WO2008129308A2 (en) | 2007-04-24 | 2008-04-24 | Drug combination and its use in the treatment of muscle loss |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200970957A1 true EA200970957A1 (ru) | 2010-04-30 |
EA018918B1 EA018918B1 (ru) | 2013-11-29 |
Family
ID=39639100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970957A EA018918B1 (ru) | 2007-04-24 | 2008-04-24 | КОМБИНАЦИЯ, СОДЕРЖАЩАЯ β-АГОНИСТ И ПРОГЕСТИН, И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ АТРОФИИ МЫШЕЧНОЙ ТКАНИ |
Country Status (16)
Country | Link |
---|---|
US (1) | US8653052B2 (ru) |
EP (1) | EP2155180B1 (ru) |
JP (1) | JP5627452B2 (ru) |
KR (1) | KR101546977B1 (ru) |
CN (2) | CN101730547A (ru) |
AU (1) | AU2008240379B2 (ru) |
BR (1) | BRPI0810461A2 (ru) |
CA (1) | CA2721739C (ru) |
DK (1) | DK2155180T3 (ru) |
EA (1) | EA018918B1 (ru) |
ES (1) | ES2592289T3 (ru) |
HK (1) | HK1202262A1 (ru) |
IL (1) | IL201426A (ru) |
MX (1) | MX2009011294A (ru) |
NZ (1) | NZ580975A (ru) |
WO (1) | WO2008129308A2 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE457169T1 (de) | 1998-10-15 | 2010-02-15 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
CN106075449A (zh) | 2005-07-14 | 2016-11-09 | 尼奥塞蒂克斯公司 | 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂 |
GB0624282D0 (en) | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
EP2646012A4 (en) * | 2010-11-24 | 2014-12-10 | Neothetics Inc | MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT |
US9873695B2 (en) * | 2014-08-05 | 2018-01-23 | Raqualia Pharma Inc. | Serine derivatives as ghrelin receptor agonists |
IL294709B2 (en) * | 2020-01-13 | 2023-07-01 | Astromedical Biotechnology Ltd | Use of ketamine in the treatment of exhaustion |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3855801T2 (de) | 1987-09-15 | 1997-07-03 | Rowett Research Inst | Anwendungsgebiete von beta-adrenergenen Agonisten |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
AU2003230885A1 (en) * | 2002-04-12 | 2003-10-27 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
ES2245612B1 (es) | 2004-06-29 | 2007-08-16 | Universidad De Barcelona | Nuevo uso terapeutico del formoterol. |
EP1991270A4 (en) | 2005-12-22 | 2009-12-02 | Anaborex Inc | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CACHEXIA |
US7947579B2 (en) | 2006-02-13 | 2011-05-24 | Stc.Unm | Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition |
-
2008
- 2008-04-24 CA CA2721739A patent/CA2721739C/en not_active Expired - Fee Related
- 2008-04-24 DK DK08737103.5T patent/DK2155180T3/en active
- 2008-04-24 MX MX2009011294A patent/MX2009011294A/es active IP Right Grant
- 2008-04-24 KR KR1020097024247A patent/KR101546977B1/ko not_active IP Right Cessation
- 2008-04-24 US US12/594,985 patent/US8653052B2/en not_active Expired - Fee Related
- 2008-04-24 NZ NZ580975A patent/NZ580975A/xx not_active IP Right Cessation
- 2008-04-24 EA EA200970957A patent/EA018918B1/ru not_active IP Right Cessation
- 2008-04-24 EP EP08737103.5A patent/EP2155180B1/en not_active Not-in-force
- 2008-04-24 WO PCT/GB2008/001452 patent/WO2008129308A2/en active Application Filing
- 2008-04-24 JP JP2010504834A patent/JP5627452B2/ja not_active Expired - Fee Related
- 2008-04-24 CN CN200880012990A patent/CN101730547A/zh active Pending
- 2008-04-24 ES ES08737103.5T patent/ES2592289T3/es active Active
- 2008-04-24 BR BRPI0810461-1A2A patent/BRPI0810461A2/pt not_active IP Right Cessation
- 2008-04-24 CN CN201410490740.8A patent/CN104306381A/zh active Pending
- 2008-04-24 AU AU2008240379A patent/AU2008240379B2/en not_active Ceased
-
2009
- 2009-10-11 IL IL201426A patent/IL201426A/en not_active IP Right Cessation
-
2015
- 2015-03-19 HK HK15102807.2A patent/HK1202262A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES2592289T3 (es) | 2016-11-29 |
US8653052B2 (en) | 2014-02-18 |
EP2155180A2 (en) | 2010-02-24 |
EA018918B1 (ru) | 2013-11-29 |
KR101546977B1 (ko) | 2015-08-24 |
EP2155180B1 (en) | 2016-07-13 |
CA2721739C (en) | 2016-08-23 |
DK2155180T3 (en) | 2016-09-12 |
WO2008129308A2 (en) | 2008-10-30 |
KR20100017205A (ko) | 2010-02-16 |
US20100130456A1 (en) | 2010-05-27 |
AU2008240379B2 (en) | 2012-10-04 |
BRPI0810461A2 (pt) | 2014-10-14 |
IL201426A0 (en) | 2010-05-31 |
AU2008240379A1 (en) | 2008-10-30 |
CA2721739A1 (en) | 2008-10-30 |
CN104306381A (zh) | 2015-01-28 |
JP5627452B2 (ja) | 2014-11-19 |
WO2008129308A3 (en) | 2009-12-17 |
MX2009011294A (es) | 2010-01-29 |
JP2010525044A (ja) | 2010-07-22 |
NZ580975A (en) | 2012-10-26 |
IL201426A (en) | 2016-09-29 |
HK1202262A1 (en) | 2015-09-25 |
CN101730547A (zh) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1991218A4 (en) | USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES | |
MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
EA200970957A1 (ru) | Лекарственная комбинация и её применение при лечении атрофии мышечной ткани | |
EA201100544A1 (ru) | Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли | |
EA201690265A2 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
IL182218A0 (en) | Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity | |
MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
MA33076B1 (fr) | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer | |
IL192299A0 (en) | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | |
EA201370208A1 (ru) | Формы рифаксимина и их применение | |
JO2686B1 (en) | Vehicles | |
ATE468849T1 (de) | Idebenon zur behandlung von muskeldystrophien | |
IL178827A0 (en) | Use of reboxetine for the treatment of pain | |
WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
TW200716082A (en) | Combination and use of drugs | |
DE602007007934D1 (en) | Imidazoazephinonverbindungen | |
EP2124554A4 (en) | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | |
WO2007104933A8 (en) | Chemical compounds | |
BRPI0407039A (pt) | Uso de uma combinação de um inibidor de aromatase, uma progestina e um estrogênio, composição farmacêutica, e, método do tratamento de endometriose | |
EA201000738A1 (ru) | Медицинское применение 3-(2,2,2-триметилгидразиниум)пропионат гидрофумарата и дигидрофосфата | |
RS52038B (en) | USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS | |
EA200801023A1 (ru) | Применение фенофибрата или его производного для предотвращения диабетической ретинопатии | |
WO2008028888A3 (en) | Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting | |
SG143202A1 (en) | Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia | |
WO2006017921A8 (en) | Selective muscle relaxant and pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |